-$1.48 Earnings Per Share Expected for Atara Biotherapeutics Inc (ATRA) This Quarter
Analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share (EPS) of ($1.48) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.51) to ($1.44). Atara Biotherapeutics posted earnings of ($1.05) per share in the same quarter last year, which suggests a negative year over year growth rate of 41%. The business is expected to announce its next quarterly earnings results on Tuesday, May 14th.
On average, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.99) per share for the current financial year, with EPS estimates ranging from ($6.11) to ($5.79). For the next fiscal year, analysts anticipate that the company will report earnings of ($5.70) per share, with EPS estimates ranging from ($6.18) to ($5.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Tuesday, February 26th. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.31) by ($0.44).
Shares of Atara Biotherapeutics stock traded up $1.80 on Tuesday, hitting $33.49. 318,363 shares of the company traded hands, compared to its average volume of 459,776. The stock has a market cap of $1.46 billion, a P/E ratio of -6.35 and a beta of 2.25. Atara Biotherapeutics has a 12-month low of $27.85 and a 12-month high of $54.45.
In related news, CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction on Thursday, January 24th. The shares were sold at an average price of $35.06, for a total value of $273,468.00. Following the transaction, the chief executive officer now owns 433,111 shares in the company, valued at approximately $15,184,871.66. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Derrell Porter sold 5,909 shares of Atara Biotherapeutics stock in a transaction on Friday, February 15th. The stock was sold at an average price of $40.00, for a total transaction of $236,360.00. Following the completion of the transaction, the senior vice president now owns 27,597 shares in the company, valued at approximately $1,103,880. The disclosure for this sale can be found here. In the last quarter, insiders sold 162,524 shares of company stock worth $6,069,971. 10.60% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Vanguard Group Inc raised its position in Atara Biotherapeutics by 4.5% in the 3rd quarter. Vanguard Group Inc now owns 2,487,567 shares of the biotechnology company’s stock worth $102,861,000 after purchasing an additional 106,213 shares during the period. Neuberger Berman Group LLC grew its holdings in Atara Biotherapeutics by 6.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 1,218,539 shares of the biotechnology company’s stock worth $50,386,000 after acquiring an additional 74,833 shares during the last quarter. SG Americas Securities LLC bought a new stake in Atara Biotherapeutics in the 3rd quarter worth $108,000. Dimensional Fund Advisors LP grew its holdings in Atara Biotherapeutics by 1,801.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 229,141 shares of the biotechnology company’s stock worth $9,474,000 after acquiring an additional 217,088 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in Atara Biotherapeutics by 12.7% in the 3rd quarter. AQR Capital Management LLC now owns 21,609 shares of the biotechnology company’s stock worth $894,000 after acquiring an additional 2,439 shares during the last quarter.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More: What is a Candlestick Chart?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.